DK1500654T3 - Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler - Google Patents

Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler

Info

Publication number
DK1500654T3
DK1500654T3 DK03712152T DK03712152T DK1500654T3 DK 1500654 T3 DK1500654 T3 DK 1500654T3 DK 03712152 T DK03712152 T DK 03712152T DK 03712152 T DK03712152 T DK 03712152T DK 1500654 T3 DK1500654 T3 DK 1500654T3
Authority
DK
Denmark
Prior art keywords
pharmaceuticals
preparation
benzoxazinone derivatives
benzoxazinone
derivatives
Prior art date
Application number
DK03712152T
Other languages
English (en)
Inventor
Antonio Torrens-Jover
Jose Aurelio Castrillo-Perez
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of DK1500654T3 publication Critical patent/DK1500654T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DK03712152T 2002-04-09 2003-04-09 Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler DK1500654T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
DK1500654T3 true DK1500654T3 (da) 2006-06-06

Family

ID=28686085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03712152T DK1500654T3 (da) 2002-04-09 2003-04-09 Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler

Country Status (29)

Country Link
US (3) US7056914B2 (da)
EP (2) EP1497285B1 (da)
JP (1) JP2005529866A (da)
KR (1) KR20050008679A (da)
CN (1) CN1659164A (da)
AR (2) AR039256A1 (da)
AT (2) ATE489382T1 (da)
AU (2) AU2003222804A1 (da)
BR (1) BR0309083A (da)
CA (1) CA2481701A1 (da)
DE (2) DE60335094D1 (da)
DK (1) DK1500654T3 (da)
EC (1) ECSP045353A (da)
ES (3) ES2193875B2 (da)
HK (1) HK1069820A1 (da)
HR (1) HRP20040919A2 (da)
IL (1) IL164442A0 (da)
IS (1) IS7491A (da)
MA (1) MA27692A1 (da)
MX (1) MXPA04009889A (da)
NO (1) NO20044322L (da)
NZ (1) NZ536167A (da)
PL (1) PL372537A1 (da)
PT (1) PT1500654E (da)
RU (1) RU2004133041A (da)
TN (1) TNSN04203A1 (da)
UA (1) UA79460C2 (da)
WO (2) WO2003084952A1 (da)
ZA (1) ZA200408275B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン－１－カルボキサミド誘導体
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
JP2008523110A (ja) * 2005-03-21 2008-07-03 ザ プロクター アンド ギャンブル カンパニー 視覚的に区別できる相を含む多相パーソナルケア組成物
CA2603299A1 (en) * 2005-04-13 2006-10-26 The Procter & Gamble Company Structured multi-phased personal care composition comprising branched anionic surfactants
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
WO2007066310A2 (en) * 2005-12-08 2007-06-14 The Procter & Gamble Company A container comprising an in-mold label positioned proximate to a surface topography
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
CA2660799C (en) * 2006-08-14 2013-03-19 Council Of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
CA2187767A1 (en) 1994-04-14 1995-10-26 Joel R. Huff Alpha1c adrenergic receptor antagonists
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU1698997A (en) 1996-01-16 1997-08-11 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0955293B1 (en) 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
AU6144098A (en) 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1329589A (zh) 1998-10-07 2002-01-02 奥索-麦克尼尔药品公司 用作神经肽yy5受体的配体的n－芳烷基氨基1,2,3,4－四氢萘
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
EP1206262A4 (en) 1999-08-26 2003-01-02 Bristol Myers Squibb Co Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
ATE427935T1 (de) * 2001-08-07 2009-04-15 Banyu Pharma Co Ltd Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
ECSP045353A (es) 2005-01-28
DE60303440D1 (de) 2006-04-13
NO20044322L (no) 2004-10-12
US7514429B2 (en) 2009-04-07
EP1497285A1 (en) 2005-01-19
US7041665B2 (en) 2006-05-09
EP1500654A1 (en) 2005-01-26
MA27692A1 (fr) 2006-01-02
IS7491A (is) 2004-10-06
CN1659164A (zh) 2005-08-24
PL372537A1 (en) 2005-07-25
TNSN04203A1 (en) 2007-03-12
WO2003084939A1 (es) 2003-10-16
CA2481701A1 (en) 2003-10-16
JP2005529866A (ja) 2005-10-06
MXPA04009889A (es) 2005-08-16
ATE489382T1 (de) 2010-12-15
AU2003216934A1 (en) 2003-10-20
KR20050008679A (ko) 2005-01-21
DE60303440T2 (de) 2006-10-26
US20040067941A1 (en) 2004-04-08
US20060128701A1 (en) 2006-06-15
US7056914B2 (en) 2006-06-06
DE60335094D1 (de) 2011-01-05
EP1500654B1 (en) 2006-02-01
PT1500654E (pt) 2006-06-30
AR048567A1 (es) 2006-05-10
IL164442A0 (en) 2005-12-18
WO2003084952A1 (en) 2003-10-16
ZA200408275B (en) 2006-04-26
ES2193875A1 (es) 2003-11-01
US20040058920A1 (en) 2004-03-25
UA79460C2 (en) 2007-06-25
EP1497285B1 (en) 2010-11-24
ES2258219T3 (es) 2006-08-16
HRP20040919A2 (en) 2005-04-30
BR0309083A (pt) 2005-04-19
AU2003222804A1 (en) 2003-10-20
ATE316966T1 (de) 2006-02-15
NZ536167A (en) 2006-06-30
AR039256A1 (es) 2005-02-16
ES2193875B2 (es) 2005-03-01
ES2356815T3 (es) 2011-04-13
HK1069820A1 (en) 2005-06-03
RU2004133041A (ru) 2005-09-10

Similar Documents

Publication Publication Date Title
DK1500654T3 (da) Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
DK1368349T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DK1532149T3 (da) 8-[3-amino-piperiden-1-yl]-xanthiner, fremstilling deraf og anvendelse deraf som lægemiddel
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DK1562946T3 (da) Nye xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20052995D0 (no) 1,5-diaryl-pyrrol-3-karboksamid-derivater, og deres anvendelse som kannabinoid reseptormodulatorer.
NO20006029D0 (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
DK1445252T3 (da) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
IS2641B (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1506179T3 (da) Benzoxazinderivater som 5-HT6-modulatorer og anvendelser deraf
NO20043349L (no) Kumarinderivater, fremgangsmate for deres framstilling og anvendelse derav
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20053588D0 (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
DK1523473T3 (da) Indolinderivater substitueret i position 6, deres fremstilling og anvendelse som lægemiddel.
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.